The Degree of Inflammation and Length of Hospital Stay in Acute Exacerbation of COPD Patients After Secretome Administration

Hendrastutik Apriningsih, Yusup Subagio Sutanto, Reviono Reviono, Artrien Adhiputri, Windu Prasetya, Fahlevie Fahlevie, Fitrotin Aziza


Background: Acute exacerbation of COPD (AECOPD) is a decrease in respiratory conditions compared with regular conditions that require additional treatment, increase risk of hospitalization or demand intensive care unit. The neutrophil-to-lymphocyte ratio (NLR) describes the balance between the severity of inflammation and the immune system and is considered as an important systemic inflammatory marker. Length of hospital stay (LHS) is important in predicting the severity of AECOPD, in which longer LHS indicates greater severity of AECOPD. Secretome has been shown to have the ability to exert immunomodulatory effects, reduce lung injury and inflammation in several models of lung inflammation and immune-mediated lung disease. This study aimed to assess the differences between NLR and LHS in AECOPD patients who received a secretome and those who did not.

Methods: This study involved 30 AECOPD patients whom assigned into two groups. Secretome and standard therapy were administered in the treatment group, whilst the control group only received the standard therapy. Statistical analysis used different test, the unpaired group difference test using Mann Whitney and the independent test, the paired group difference test using Wilcoxon rank test and Pair test. Result is significant if the P<0.05.

Results: NLR value in the treatment group experienced a lower increase than the control group, yet statistically insignificant (P=0,187). Secretome decreased the LHS in AECOPD patients, and statistically significant with (P=0,028).

Conclusion: Administration of secretome led to a lower increase in NLR value and decreased LHS AECOPD patients.


acute exacerbation of COPD, secretome, NLR, LHS

Full Text:



Agusti A, Beasley R, Celli BR, Criner GJ, Halpin D, Varela M, et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report. 2022;

Fazleen A, Wilkinson T. Early COPD: current evidence for diagnosis and management. Ther Adv Respir Dis. 2020;14:1-13.

Soriano JB, Abajobir AA, Abate KH, Abera SF, Agrawal A, Ahmed MB, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691-706.

Sutradhar I, Das Gupta R, Hasan M, Wazib A, Sarker M. Prevalence and Risk Factors of Chronic Obstructive Pulmonary Disease in Bangladesh: A Systematic Review. Cureus. 2019;11(1):1-14.

Hoogendoorn M, Feenstra TL, Boland M, Briggs AH, Borg S, Jansson SA, et al. Prediction models for exacerbations in different COPD patient populations: Comparing results of five large data sources. Int J COPD. 2017;12:3183-94.

Hurst JR, Skolnik N, Hansen GJ, Anzueto A, Donaldson GC, Dransfield MT, et al. Understanding the impact of chronic obstructive pulmonary disease exacerbations on patient health and quality of life. Eur J Intern Med. 2020;73:1-6.

Firdausi NL, Artanti KD, Li C-Y. Analysis of Risk Factors Affecting The Occurrence of Chronic Obstructive Pulmonary Disease in Indonesia. J Berk Epidemiol. 2021;9(1):18.

Andari F, Damayanti T. Role of Mesenchymal Stem Cells In Chronic Obstructive Lung Disease. Respir Sci. 2021;1(3):202-12.

Wang H, Yang T, Yu X, Chen Z, Ran Y, Wang J, et al. Risk Factors for Length of Hospital Stay in Acute Exacerbation Chronic Obstructive Pulmonary Disease: A Multicenter Cross-Sectional Study. Int J Gen Med. 2022;15(3):3447-58.

Torabipour A, Hakim A, Angali KA, Dolatshah M, Yusofzadeh M. Cost analysis of hospitalized patients with chronic obstructive pulmonary disease: A state-level cross-sectional study. Tanaffos. 2016;15(2):75-82.

Hlapcic I, Belamaric D, Bosnar M, Kifer D, Dugac AV, Rumora L. Combination of systemic inflammatory biomarkers in assessment of chronic obstructive pulmonary disease: Diagnostic performance and identification of networks and clusters. Diagnostics. 2020;10(12):1-15.

Perng DW, Chen PK. The relationship between airway inflammation and exacerbation in chronic obstructive pulmonary disease. Tuberc Respir Dis (Seoul). 2017;80(4):325-35.

Chen YT, Miao K, Zhou L, Xiong WN, Wei PF. Stem cell therapy for chronic obstructive pulmonary disease. Chin Med J (Engl). 2021;134(13):1535-45.

Kumar L P, Kandoi S, Misra R, S. V, K. R, Verma RS. The mesenchymal stem cell secretome: A new paradigm towards cell-free therapeutic mode in regenerative medicine. Cytokine Growth Factor Rev. 2019;46(4):1-9.

Weiss DJ, Segal K, Casaburi R, Hayes J, Tashkin D. Effect of mesenchymal stromal cell infusions on lung function in COPD patients with high CRP levels. Respir Res. 2021;22(1):1-11.

Mushlin AI, Black ER, Connolly CA, Buonaccorso KM, Eberly SW. The Necessary Length of Hospital Stay for Chronic Pulmonary Disease. JAMA J Am Med Assoc. 1991;266(1):80-3.

Crisafulli E, Ielpo A, Barbeta E, Ceccato A, Huerta A, Gabarrús A, et al. Clinical variables predicting the risk of a hospital stay for longer than 7 days in patients with severe acute exacerbations of chronic obstructive pulmonary disease: A prospective study. Respir Res. 2018;19(1):1-12.

Wedzicha JA, Brill SE, Allinson JP, Donaldson GC. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med. 2013;11(1):1-10.

Armitage JD, Tan DBA, Sturm M, Moodley YP. Transcriptional profiling of circulating mononuclear cells from patients with chronic obstructive pulmonary disease receiving mesenchymal stromal cell infusions. Stem Cells Transl Med. 2021;(1):1470-81.

Furutate R, Ishii T, Motegi T, Hattori K, Kusunoki Y, Gemma A, et al. The neutrophil to lymphocyte ratio is related to disease severity and exacerbation in patients with chronic obstructive pulmonary disease. Intern Med. 2016;55(3):223-9.

Alqahtani JS, Njoku CM, Bereznicki B, Wimmer BC, Peterson GM, Kinsman L, et al. Risk factors for all-cause hospital readmission following exacerbation of COPD: A systematic review and meta-analysis. Eur Respir Rev. 2020;29(156):1-16.

Li M, Cheng K, Ku K, Li J, Hu H, Ung C. Factors influencing the length of hospital stay among patients with chronic obstructive pulmonary disease (COPD) in Macao population: A retrospective study of inpatient health record. Int J COPD. 2021;16:1677-8.



  • There are currently no refbacks.

Copyright (c) 2023 Hendrastutik Apriningsih, Yusup Subagio Sutanto, Reviono, Artrien Adhiputri, Windu Prasetya, Fahlevie, Fitrotin Aziza


SINTA Garuda Indonesian Scientific Journal Database (ISJD) Indonesia One Search (IOS) Crossref

ROAD-ISSN Dimensions Google Scholar 


Jurnal Respirologi Indonesia
pISSN: 0853-7704 - eISSN: 2620-3162
Address: Jalan Cipinang Bunder No. 19, Cipinang, Pulogadung, Jakarta Timur, DKI Jakarta 13240, Indonesia
Phone: +62-21-2247-4845

An official publication by
the Indonesian Society of Respirology (ISR)

Creative Commons License
Creative Commons Attribution-NonCommercial 4.0 International License